ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals, which are implicated as a major contributor to severe asthma and to the persistence of mucus plugs.
ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D. who identified the first novel airway inflammation target in decades.